Treatment of pulmonary tuberculosis

Area of Science:

• Medicine
• Infectious Diseases
• Public Health

Background:

• Tuberculosis treatment duration in The Netherlands shortened to six months.
• Standard six-month regimen (2HRZ/2HR) effective for drug-susceptible tuberculosis.
• Increasing global prevalence of drug-resistant tuberculosis necessitates treatment adjustments.

Purpose of the Study:

• To outline current tuberculosis treatment strategies in light of drug resistance.
• To provide guidance on drug selection for intensive and retreatment regimens.
• To emphasize the importance of patient compliance and monitoring.

Main Methods:

• Review of current tuberculosis treatment guidelines and drug resistance patterns.
• Discussion of empirical treatment strategies based on susceptibility testing availability.
• Consideration of specific patient populations (e.g., previously treated, HIV-infected).

Main Results:

• A six-month regimen is effective for susceptible tuberculosis.
• Empirical addition of ethambutol is recommended when susceptibility is unknown.
• Retreatment requires at least two new drugs, with amikacin preferred over streptomycin.
• Treatment duration for extrapulmonary and HIV-infected TB remains under discussion, with some severe cases requiring 9-12 months.

Conclusions:

• Treatment protocols must adapt to rising drug resistance.
• Careful drug selection and patient monitoring are vital for successful tuberculosis treatment.
• Public health nurse involvement is essential for ensuring compliance and treatment success.